Biocardia biotherapeutic delivery and morph access innovations business development update for shareholders

Sunnyvale, calif., jan. 03, 2024 (globe newswire) -- biocardia, inc. (nasdaq: bcda), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, issues the following letter to shareholders:
BCDA Ratings Summary
BCDA Quant Ranking